CRBP CEO Cohen Yuval sold 63,358 shares ($3.0M) across 8 transactions Jun 14–18 at $46.57 avg, reducing holdings 45.1%
Cohen Yuval, Chief Executive Officer of Corbus Pharmaceuticals, executed 8 separate sales totaling 63,358 shares for $2,950,518.18 over a four-day period, reducing his holdings from 140.6K shares to 77.2K shares (-45.1% of pre-transaction holdings). The sales occurred at prices ranging from $50.17 to $42.24 (blended average $46.57), while the company currently trades at $43.81 (-17.2% from its 52-week high of $52.89). Most significant is the company's financial position: latest quarterly revenue is $0.00, full-year net income was $-6.9M, and annual revenue growth shows -100.0%, indicating the company is in a non-revenue-generating stage with ongoing losses. The combination of substantial CEO equity reduction at a time when the stock price has declined from transaction levels and the company operates without revenue warrants close examination of the strategic context and timing drivers behind this multi-tranche disposition.